These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 35870032)

  • 1. Adenosine receptor signalling in Alzheimer's disease.
    Trinh PNH; Baltos JA; Hellyer SD; May LT; Gregory KJ
    Purinergic Signal; 2022 Sep; 18(3):359-381. PubMed ID: 35870032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theobromine-Induced Changes in A1 Purinergic Receptor Gene Expression and Distribution in a Rat Brain Alzheimer's Disease Model.
    Mendiola-Precoma J; Padilla K; Rodríguez-Cruz A; Berumen LC; Miledi R; García-Alcocer G
    J Alzheimers Dis; 2017; 55(3):1273-1283. PubMed ID: 27792010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purinergic receptors as potential therapeutic targets in Alzheimer's disease.
    Woods LT; Ajit D; Camden JM; Erb L; Weisman GA
    Neuropharmacology; 2016 May; 104():169-79. PubMed ID: 26519903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiological Role and Medicinal Chemistry of A
    Merighi S; Borea PA; Varani K; Vincenzi F; Travagli A; Nigro M; Pasquini S; Suresh RR; Kim SW; Volkow ND; Jacobson KA; Gessi S
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of adenosine A
    Launay A; Nebie O; Vijaya Shankara J; Lebouvier T; Buée L; Faivre E; Blum D
    Neuropharmacology; 2023 Mar; 226():109379. PubMed ID: 36572177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of purinergic receptors in the Alzheimer's disease.
    Cieślak M; Wojtczak A
    Purinergic Signal; 2018 Dec; 14(4):331-344. PubMed ID: 30362042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies.
    Takahashi RN; Pamplona FA; Prediger RD
    Front Biosci; 2008 Jan; 13():2614-32. PubMed ID: 17981738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine for Prevention of Alzheimer's Disease: Is the A
    Merighi S; Travagli A; Nigro M; Pasquini S; Cappello M; Contri C; Varani K; Vincenzi F; Borea PA; Gessi S
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A
    Merighi S; Borea PA; Varani K; Vincenzi F; Jacobson KA; Gessi S
    Curr Med Chem; 2022; 29(24):4138-4151. PubMed ID: 34844537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease.
    Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
    Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.
    Qiu WQ
    Neuroscience; 2017 Jul; 356():44-51. PubMed ID: 28528968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of G protein-coupled receptors in the pathology of Alzheimer's disease.
    Thathiah A; De Strooper B
    Nat Rev Neurosci; 2011 Feb; 12(2):73-87. PubMed ID: 21248787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease.
    Ma WH; Chen AF; Xie XY; Huang YS
    Neuropharmacology; 2021 Jun; 190():108342. PubMed ID: 33045243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.
    Viola KL; Klein WL
    Acta Neuropathol; 2015 Feb; 129(2):183-206. PubMed ID: 25604547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine receptor control of cognition in normal and disease.
    Chen JF
    Int Rev Neurobiol; 2014; 119():257-307. PubMed ID: 25175970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purinergic signaling in Alzheimer's disease.
    Erb L; Woods LT; Khalafalla MG; Weisman GA
    Brain Res Bull; 2019 Sep; 151():25-37. PubMed ID: 30472151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins.
    Pavía J; de Ceballos ML; Sanchez de la Cuesta F
    Fundam Clin Pharmacol; 1998; 12(5):473-81. PubMed ID: 9794144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.